The components of the cardiac conduction system are illustrated in Figure 1. Arrhythmias can arise from various mechanisms, primarily categorized into abnormal impulse initiation and impulse conduction, or re-entry of impulses in the heart’s electrical system. The different mechanisms precipitate varying classifications of the disease, including tachyarrhythmia and bradyarrhythmia.⁹ Within the subcategories of tachyarrhythmia, AF is characterized by rapid and irregular electrical signals in the atria, whereas organized electrical activity in the atria represents an atrial flutter. SVT encompasses arrhythmias originating above the ventricles, leading to a rapid heart rate, and ventricular arrhythmias, including VF, represent a more critical form of the disease. In bradyarrhythmia, an atrioventricular block may occur when conduction through the node is impaired, thereby leading to symptomatic or asymptomatic manifestations depending on the degree of the block.²

Multiple risk factors, such as lifestyle factors and electrolyte imbalance triggers, and underlying conditions, including viral infections, congenital heart defects, and autonomic nervous system imbalances, can predispose individuals to arrhythmogenesis.¹⁰ In particular, degenerative electrical disease and left ventricular hypertrophy constitute a principal pathophysiological mechanism.⁸ Similarly, structural heart diseases, such as coronary artery disease, cardiomyopathy, and valvular heart disease, can alter the heart’s anatomy and electrical properties, increasing the likelihood of arrhythmias.

With considerable evidence linking hypertension with cardiac arrhythmias, recent reports have suggested that various antihypertensive agents prescribed for the management of hypertension in patients can also contribute to the manifestation of arrhythmias, mainly through electrolyte disturbances. It is estimated that people with hypertension or taking antihypertensive medication have a 73% greater likelihood of AF. According to Lip et al.,⁴ caution should be exercised with the concomitant use of non-dihydropyridine calcium channel blockers and β-blockers in the management of hypertension, as this portends an increased risk of bradycardia and atrioventricular block, particularly in patients with chronic kidney disease.

Cardiac arrhythmias can present with a wide range of symptoms, which carry immediate risk depending on the type and underlying cardiac function. Symptoms may include palpitations, dizziness, lightheadedness, chest discomfort, fatigue, and anxiety.¹¹ However, although AF is commonly symptomatic, it remains clinically silent in up to 35% of cases, especially among individuals with minimal comorbidity, such as isolated hypertension.⁴ This asymptomatic nature presents a diagnostic challenge, as untreated AF markedly increases the risk of thromboembolic events, particularly ischemic stroke, due to stasis of blood within the atria.

Other clinical manifestations of cardiac arrhythmias include irregular heartbeats, pre-syncope or syncope, chest tightness, and shortness of breath. In severe cases, arrhythmias may precipitate hemodynamic instability or sudden cardiac arrest.¹² Complications, including the development of heart failure secondary to impaired ventricular filling and output, and progression to more malignant arrhythmias, can also occur.¹ However, the prognosis of cardiac arrhythmias depends on timely diagnosis, the presence of comorbidities, and individualized therapeutic interventions.

Early identification and management of cardiac arrhythmia is critical; if left unmanaged, it can lead to severe complications, including stroke, heart failure, and sudden cardiac death. In response to this need, techniques, including photoplethysmography and ECG signaling, have been used for the diagnosis of arrhythmias. The ECG is often the first and primary diagnostic modality performed for suspected cases of arrhythmia, as it records the heart’s electrical activity. Specifically, heart rate variability and abnormal heart rhythms can be estimated from ECG signals and can reveal whether there is dysregulation of the autonomic system.¹³

Recent advances in biomedical engineering have introduced techniques such as the Holter monitoring system and event recorders, involving a portable ECG device that continuously records the heart’s electrical activity for 24 to 48 h or longer, or only when the patient experiences symptoms. These modalities offer non-invasive, real-time data collection and may enhance diagnostic precision outside of clinical settings, as well as help to identify intermittent or transient arrhythmias that may not be present during a standard ECG.¹⁴

Beyond standard ECG diagnosis, a comprehensive arrhythmia assessment may involve a combination of other baseline clinical assessments, including the patient’s medical history, physical examination, and the results of diagnostic tests. The WHO functional class and six-minute walk test are used to assess physical capacity and cardiovascular response to exertion.¹⁵ Echocardiography and cardiac magnetic resonance imaging¹⁶ are also being used to visualize cardiac chamber dimensions, valvular function, and systolic performance, providing insights into structural anomalies that may underlie rhythm disturbances.^17,18 These assessment modalities underscore the need for a multidisciplinary approach involving precise measurement, longitudinal monitoring, and personalized evaluation for optimizing patient outcomes.

It is therefore recommended that healthcare providers consider the specific arrhythmic symptoms, the duration and frequency of the irregular heartbeats, and underlying medical conditions to determine the most effective approaches to diagnosing and managing the varying forms of arrhythmia. The findings from this narrative review will highlight the evolving landscape of cardiac arrhythmia management, which is crucial for supporting clinicians in the development of safer regimens and informing future research directions in the management of arrhythmia.

Given the impact of dietary habits on cardiac rhythm, current clinical guidelines recommend the Dietary Approaches to Stop Hypertension (DASH) plan as one of the first and particularly effective strategies for preventing and reducing cardiac arrhythmias. Diets high in potassium, magnesium, calcium, omega-3 fatty acids, dietary fiber, and lignans have demonstrated protective effects on vascular tone and cardiac excitability, thereby also contributing to arrhythmia prevention. In the FLAX-PAD trial (Table 1), a 1-year consumption of a diet supplemented with 30 g of milled flaxseed–a plant protein rich in omega-3 fatty acids, dietary fiber, and lignans–demonstrated a 2% decrease in the presence of cardiac arrhythmias without any significant change in ECG variables.²⁰ Additionally, coffee and other related foods such as tea, nuts, chocolates, and antioxidant vitamins have also been proposed to potentially have antiarrhythmic properties.²¹ However, uncertainty still persists regarding the harms or benefits of these foods, especially meals with chocolates and caffeine. Similarly, energy drinks and meals rich in polyunsaturated and monounsaturated fatty acids, and salts, are required to be taken in limited quantities, as they may be harmful for patients with rhythm disorders.²²

Obesity and overweight remain strong risk factors for cardiac arrhythmias, with each 5-unit increase in body mass index resulting in a corresponding 19–29% increase in incident AF.²³ While obesity is linked to higher risks of atrial and ventricular arrhythmias, as well as sudden cardiac death, reports have demonstrated the effect of weight loss in mitigating arrhythmic incidence. According to reports from Abed et al.,²⁴ patients with symptomatic AF who underwent weight management experienced superior reductions in the disease burden, symptom severity scores, cumulative duration, and interventricular septal thickness, compared to patients who did not.

Two primary papers in this review buttressed the importance of weight loss for reduced AF incidence. First, the LEGACY study,²⁵ which assessed long-term outcomes, indicated that patients with weight loss of >10% exhibited lower arrhythmic burden and greater survival-free rates. Similarly, the REVERSE-AF study demonstrated that patients with the greatest degree of weight loss had the lowest rates of progression from paroxysmal to persistent AF, as well as the highest rates of reversal,²⁶ thereby highlighting the importance of weight loss in arrhythmia management. However, it is crucial to ensure that weight loss is gradual and nutritionally sound. Excessive or rapid weight loss, particularly from restrictive diets or malabsorptive conditions, may precipitate electrolyte imbalances, such as hypokalemia or hypomagnesemia, which can result in cardiac arrhythmias through disruption of myocardial conduction and repolarization.²⁷

In line with the need for weight loss, regular physical activity is generally considered a protective intervention against arrhythmia. Reports have shown that leisure-time physical activity is associated with a lower incidence of AF in a graded manner.²⁸ Maintenance of proper glycemic control through structured exercise training for prediabetes and continuous positive airway pressure utilization for obstructive sleep apnea has also been correlated with reductions in AF recurrence. Moderate exercise has been shown to demonstrate greater arrhythmia-free survival and a mean reduction in the disease burden; as such, routine physical activity, including aerobic exercises, is paramount and can improve endothelial function, modulate autonomic balance, and enhance cardiac output.²⁹

Anxiety, depression, stress, poor quality of life, and other related aspects of psychological health significantly influence the clinical course and prognosis of both ventricular and atrial arrhythmias through their impact on autonomic activity.³⁰ To address these factors, interventions aimed at decreasing psychological and physiological responses have been proposed. Recently, psychologically based techniques such as biofeedback, relaxation training, meditation, hypnosis, and psychotherapy have been used in the treatment of certain patients with cardiac arrhythmias. A case report by Park and Roth³¹ demonstrates the efficacy of the biofeedback system. Similarly, 6-month cognitive behavioral therapy represents a promising nonpharmacological intervention for managing arrhythmias and improving both psychological and physical quality of life.^32,33 Enacting cognitive behavioral changes using the five A’s, which include patient assessment, advice, agreement, assistance, and arrangement, has been shown to significantly improve physical and emotional well-being in patients with atrial fibrillation.

Social modulators and behavioral counseling strategies have also provided favorable modifications in patients who may struggle to implement and maintain therapeutic lifestyle interventions against smoking, or excessive alcohol or caffeine intake. As smoking cessation is imperative to arrhythmia management due to its pro-arrhythmic and vasoconstrictive effects of tobacco use. Likewise, alcohol should be consumed in moderation or avoided altogether in patients with known arrhythmic predisposition. Through cognitive behavioral therapy and other modalities such as psychological stress management, mindfulness practices, and adequate sleep hygiene, patients can be motivated to overcome these predisposing risk factors and unhealthy lifestyle habits, thus modulating autonomic tone and reducing adrenergic surges that may trigger arrhythmias.³³

Arrhythmic medications can be further grouped according to their electrophysiological effects at a cellular level using the Vaughan Williams classification or according to their main sites of action within the heart to maintain sinus rhythm.³⁵ Using the Vaughan Williams classification, antiarrhythmic therapy can be categorized into four classes: Class I, sodium channel blockers; Class II, beta blockers; Class III, potassium channel blockers; and Class IV, calcium channel blockers. Rate control involves using Class II or Class IV medications to slow the heart rate, whereas rhythm control requires the use of Class I or Class III medications for normal heart rhythm restoration.³⁶ Other agents include adenosine and digoxin for paroxysmal SVT and rate control in AF, respectively.³⁷ Figure 2 shows the Vaughan classification of antiarrhythmic drugs.

The choice between rate and rhythm control therapy depends on factors such as symptom severity, duration of arrhythmia, and patient preferences. However, recent updates in the management of AF now report that early rhythm control should be favored over rate control in select patients, especially those with recent onset, structural heart disease, or high stroke risk.³⁸ Similarly, due to adverse effects such as QT prolongation and anticholinergic effects in Class IA anti-arrhythmics, and proarrhythmic and conduction blocks in Class IC drugs, these medications are contraindicated in patients with prolonged QT and prior myocardial infarction or reduced ejection fraction, respectively.³⁹

Major clinical trials have shaped the management of AF and the choice between rate and rhythm control. In the AFFIRM trial,⁴⁰ patients who took rhythm-control drugs like amiodarone, sotalol, or propafenone had a 5-year mortality of 23.8%, compared with 21.3% for those on rate-control medications such as beta-blockers, calcium channel blockers, or digoxin; however, these differences were not significant (hazard ratio [HR]: 1.15; 95% confidence interval [CI]: 0.99–1.34; p = 0.08). Notably, hospitalizations were slightly higher in the rhythm-control group (80.1% vs. 73.0%; p < 0.001). Therefore, the study concluded that rhythm control using antiarrhythmic drugs offered no survival advantage over rate control.

Likewise, the RACE I trial,⁴¹ involving over 500 patients with persistent AF, similarly found that rate control was as effective as rhythm control; the main cardiovascular events occurred in 17.2% of the rate-control group versus 22.6% in the rhythm-control group (HR: 0.73; 95% CI: 0.53–1.01). Building on findings from the previous studies, the RACE II trial⁴² compared strict (resting heart rate <80 bpm) and lenient (resting heart rate <110 bpm) heart rate targets in patients with permanent AF. The study defined a primary outcome, which was a composite of death from cardiovascular causes and other complications. At 3 years, patients taking rate-controlling drugs who were allowed a lenient target demonstrated a similar incidence of the primary outcomes (12.9%) as those in the strict-control group (14.9%; p < 0.001). This implies that the lenient approach was just as effective as the strict approach, but more easily managed. Taken together, these landmark trials established rate control as a safe, effective, and often preferable strategy for the long-term management of atrial fibrillation, especially in patients with minimal symptoms or significant comorbidities.

Comorbidities are significant risk factors for cardiac arrhythmias. These risks may involve poor glycemic control, renal dysfunction, congenital heart defects, autonomic nervous system imbalances, viral infections like COVID-19, and cardiovascular conditions like uncontrolled hypertension. Using data from the SPRINT trial, Soliman et al.⁴³ indicated the potential effect of intensive blood pressure control in reducing AF incidence in patients, reporting a 26% lower risk of developing new AF. With a particular target on the renin–angiotensin–aldosterone system, intensive treatment to a target of systolic blood pressure <120 mm Hg in patients with hypertension has been reported to lower the risk of new-onset AF and reduce the incidence of recurrence.⁴⁴ This is important, especially as uncontrolled hypertension complicates the management of cardiac arrhythmias, diminishing the effectiveness of antiarrhythmic drugs and procedures, such as catheter ablation and cardioversion.

Similarly, the impact of diabetes on the cardiac electrical conduction system has become apparent, resulting in AF and ventricular arrhythmias.⁴⁵ Type II diabetes has been closely associated with the risk of AF development; however, glucose-lowering therapies have demonstrated effects against AF.⁴⁶ An observational study by Ostropolets et al.⁴⁷ found that patients on metformin monotherapy had a significantly reduced risk of atrial arrhythmias, compared to monotherapy with sulfonylureas, thiazolidinediones, and dipeptidyl peptidase 4 inhibitors.

Recent years have witnessed significant progress in the pharmacological management of cardiac arrhythmias, driven by advances in cardiac electrophysiology and drug development. Newer antiarrhythmic agents have been designed to improve ion channel selectivity, minimize proarrhythmic risks, and enhance overall safety and efficacy.^{48,49,50,51,52,53,54}

CASTLE-AF⁵⁵ and CAMTAF⁵⁶ trials have reported favorable outcomes regarding catheter ablation as a standard procedural therapy for the management of cardiac arrhythmias, particularly AF. In patients with paroxysmal AF, pulmonary vein isolation represents the standard approach used with newer technologies such as pulsed field ablation, offering tissue-selective ablation with reduced collateral damage. Randomized controlled trials have demonstrated favorable safety and efficacy profiles for pulsed field ablation catheters, with reduced recurrence rates and procedural complications.⁵⁹ However, in patients undergoing concomitant cardiac surgery or those with persistent arrhythmias unresponsive to catheter-based approaches, surgical options, such as the Maze procedure for AF, are introduced.⁶⁰ Left atrial appendage occlusion is a procedure that is also gaining traction for stroke prevention in patients with AF who cannot receive long-term anticoagulation therapy.⁶¹

The EAST-AFNET 4 trial⁶² showed that early rhythm control in patients with recently diagnosed atrial fibrillation, using antiarrhythmic drugs and/or catheter ablation, reduced major cardiovascular events compared with usual care focused on rate control. Over a median follow-up of 5.1 years, the primary composite outcome—cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome—occurred at 3.9 vs 5.0 per 100 person-years (HR: 0.79; 95% CI: 0.66–0.94; p = 0.005) in patients assigned to the early rhythm control group. This highlights that early rhythm control can provide a meaningful reduction in major cardiovascular events beyond symptom management.

In ventricular arrhythmias, catheter ablation guided by electroanatomic mapping and imaging modalities such as cardiac magnetic resonance imaging is increasingly used for scar-related ventricular tachycardia. Clinical trials have introduced a novel high-voltage focal pulsed field ablation catheter for VT ablation, showing promising first-in-human results.⁵⁷ Additionally, cardioneuroablation and radiofrequency ablative therapies are being explored for functional bradycardia and reflex syncope, with multicenter registry data supporting their feasibility and safety.⁵⁸

Exploration of different ablation technologies across major randomized trials has shown favorable outcomes, with different energy sources offering varying outcomes in terms of procedural performance and tissue selectivity. In the CABANA trial,⁶³ catheter ablation, compared to drug therapy, yielded a non-statistically significant reduction in the incidence of the composite of death, disabling stroke, serious bleeding, or cardiac arrest in the intention-to-treat population (8.0% vs. 9.2%; HR: 0.86; 95% CI, 0.65–1.15; p = 0.30). However, given the limitations of the study methodology, further studies are required to substantiate findings.

Trials evaluating cryothermal technology, including EARLY AF⁶⁴ and STOP AF⁶⁵ trials, demonstrated rhythm control advantages. EARLY AF⁶⁴ compared cryoablation with drug therapy as initial treatment for AF. The study reported significantly lower recurrent atrial tachyarrhythmia with first-line cryoballoon ablation within 1 year (42.9% vs. 67.8%; HR: 0.48; 95% CI: 0.35–0.66; p<0.001). Similarly, STOP AF,⁶⁵ which had a similar objective as the EARLY AF, showed 12-month freedom from symptomatic AF in 74.6% of patients in the ablation group compared with 45.0% in the drug therapy group (p < 0.001). These trials show that cryoballoon ablation delivers robust rhythm control benefits early in the treatment course and maintains safety and efficacy in broader clinical use.

Comparative evidence from the FIRE AND ICE trial⁶⁶ showed cryoballoon and radiofrequency ablation to be similar in efficacy (1-year event rate estimate: 34.6% and 35.9%, respectively; HR: 0.96; 95% CI: 0.76–1.22; p < 0.001 for noninferiority), underscoring that both thermal modalities achieve equivalent clinical outcomes despite procedural differences. The ADVENT trial⁶⁷ evaluated an emerging nonthermal ablation technology (pulsed field ablation) in comparison with conventional thermal methods for treating AF. It demonstrated that pulsed field ablation achieved noninferior acute and 12-month efficacy in maintaining sinus rhythm.

Collectively, these findings highlight how evolving ablation technologies, from radiofrequency to cryothermal to nonthermal energy sources, offer rhythm control benefits while differing in safety profiles and procedural times.

Effective management of cardiac arrhythmias requires balancing stroke prevention with bleeding risk. The CHA₂DS₂-VASc score estimates thromboembolic risk by considering factors such as heart failure, hypertension, age, diabetes, prior stroke, vascular disease, and sex, guiding decisions on anticoagulation.⁶⁸ Concurrently, the HAS-BLED score evaluates bleeding risk by assessing hypertension, renal or liver dysfunction, prior stroke or bleeding, labile INRs, age, and concomitant drug or alcohol use.⁶⁹ Combining these scores allows clinicians to identify patients who will benefit most from anticoagulation while addressing modifiable bleeding risk factors. Regular reassessment ensures ongoing therapy remains both safe and effective.

The PROTECT AF⁷⁰ and PREVAIL⁷¹ trials evaluated left atrial appendage occlusion with the Watchman device as an alternative to long-term warfarin therapy for stroke prevention in nonvalvular atrial fibrillation. The PROTECT AF⁷⁰ trial showed that Watchman implantation was noninferior to warfarin for the composite of stroke, systemic embolism, and cardiovascular death, with sustained reductions in hemorrhagic stroke and cardiovascular mortality over longer-term follow-up. The PREVAIL trial,⁷¹ designed to confirm safety and efficacy with improved operator experience, reported lower periprocedural complication rates and again demonstrated noninferiority to warfarin on key endpoints, particularly late ischemic events. Together, these trials support left atrial appendage occlusion as a viable alternative to oral anticoagulation for selected patients.

Despite substantial advancements in clinical cardiology, the management of cardiac arrhythmias still faces significant limitations. First, disease refractoriness complicates treatment, and the diverse spectrum of arrhythmias, ranging from benign premature beats to life-threatening ventricular tachycardias, adds complexity to management and drug selection. Pharmacologic management may pose risks to the patients, including proarrhythmic potential and organ-specific toxicities. For instance, many antiarrhythmic agents can paradoxically provoke arrhythmias or cause systemic damage such as pulmonary fibrosis. Additionally, some drugs suitable for AF may be harmful in structural heart disease, such as Class IC agents, which are contraindicated following myocardial infarction.³⁹ This therefore suggests the need for structured guidelines following management of cardiac arrhythmias. Second, in cases involving autonomic dysfunction-driven arrhythmias, lifestyle interventions alone are insufficient. Therefore, such recommendations should be approached with caution and tailored to the individual. Finally, although procedural advances such as pulsed field ablation and robotic navigation have improved arrhythmia management, these interventions remain constrained by high costs, limited accessibility, and risks of serious complications, including vascular injury, stroke, tamponade, and device-related infections.^57,58,59 Novel treatment modalities are therefore needed to bridge these gaps and ensure more equitable and effective patient care.

This study had some limitations. The study employed a narrative methodology, enabling a broad overview of recent developments in the clinical management of cardiac arrhythmias. However, due to its emphasis on descriptive synthesis rather than quantitative comparison, a meta-analysis was not performed. The included studies exhibited considerable heterogeneity in design and methodology, which posed challenges for direct comparison and limited the ability to draw definitive conclusions across the evidence base. The number of included studies was relatively small, given the broad scope of the topic, which may limit the generalizability of the findings and the comprehensiveness of the conclusions. Additionally, only studies published in English were considered, introducing the potential for language bias and the exclusion of relevant data from non-English publications. Although efforts were made to emphasize the relevance and contributions of each study, a formal assessment of risk of bias was not conducted, thereby constraining the depth of critical evaluation. These limitations should be considered when interpreting the results and highlight the need for further, more comprehensive research in this area.